Try our Advanced Search for more refined results
February 01, 2019
Track this case
2:19-cv-04432
New Jersey
Patent - Abbreviated New Drug Application(ANDA)
Madeline Cox Arleo
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.Additional or older documents may be available in Pacer.
Par Pharmaceutical Inc. asked a New Jersey federal court on Friday to invalidate the patent backing Merck's Janumet XR so it can begin to market a generic equivalent of the Type 2 diabetes medication as early as possible.
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login
Email (NOTE: Free email domains not supported)
First Name
Last Name
Job Title
PLEASE NOTE: A verification email will be sent to your address before you can access your trial.
Password (at least 8 characters required)
Confirm Password
Law360 may contact you in your professional capacity with information about our other products, services and events that we believe may be of interest.You’ll be able to update your communication preferences via the unsubscribe link provided within our communications.We take your privacy seriously. Please see our Privacy Policy.